8-K: Applied DNA Sciences Reports Q2 Fiscal 2025 Results: LineaRx Revenue Surges 44%

Applied DNA Sciences' LineaRx segment drives revenue growth with a 44% increase year-over-year, contributing to a 6% overall revenue increase for the second quarter of fiscal 2025.

Summary

• Applied DNA Sciences reported its financial results for the second quarter of fiscal year 2025, which ended on March 31, 2025.
• Total revenues increased by 6% to $983 thousand, compared to $930 thousand in the same quarter of the previous fiscal year.
• The LineaRx segment, focused on therapeutic DNA production, saw a 44% increase in revenues year-over-year.
• This growth was driven by large shipments to DNA manufacturing customers.
• However, the MDx Testing Services segment experienced a 33% decrease in revenues due to reduced COVID-19 surveillance testing.
• The company's operating loss was $3.5 million, slightly better than the $3.6 million loss in the prior year's quarter.
• Net loss improved to $3.3 million from $4.5 million, primarily due to the absence of a loss on warrant issuance that occurred in the previous period.
• Adjusted EBITDA remained negative at $3.3 million, consistent with the prior year.
• As of March 31, 2025, the company's cash and cash equivalents stood at $6.8 million, including $1.0 million from warrant exercises.
• The company expects quarterly cash burn to decline starting in the quarter ending June 30, 2025, following a strategic restructuring.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there are positive signs such as the growth in the LineaRx segment and the expectation of declining cash burn. The management's comments are optimistic about future opportunities.

Positives

• The LineaRx segment experienced significant revenue growth, indicating strong demand for its therapeutic DNA production services.
• The company is nearing completion of a proprietary enzyme and buffer system to enhance LinearDNA's performance.
• The company is launching LineaDNA IVT Evaluation Kits to drive adoption of the LineaIVT platform.
• The company expects quarterly cash burn to decline beginning in the quarter ending June 30, 2025.
• The company added new customers and received follow-on orders from existing customers for LineaDNA products.

Negatives

• The MDx Testing Services segment experienced a 33% decrease in revenues due to reduced COVID-19 surveillance testing.
• The company continues to operate at a loss, with an operating loss of $3.5 million and a net loss of $3.3 million for the quarter.
• Engagement with a U.S.-based therapeutics developer on a challenging self-amplifying mRNA therapy did not result in a first GMP order.

Risks

• The company's history of net losses and limited financial resources pose a risk to its long-term financial stability.
• The company's ability to remain compliant with Nasdaq listing standards is uncertain.
• Future demand for the company's biotherapeutics products and services is unknown.
• The amount of revenues and profits that will result from its Linea IVT and/or Linea DNA platforms is uncertain.
• There has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms.

Future Outlook

The company anticipates a decline in quarterly cash burn starting in the quarter ending June 30, 2025. The company believes industry tailwinds are accelerating, with substantial planned investments in U.S. manufacturing, AI drug design shortening genetic medicine development timelines, and limitations regarding the scalability, efficiency, and cost constraints of competing enzymatic DNA technologies.

Management Comments

• Dr. James A. Hayward, chairman and CEO of Applied DNA, stated that the company has emerged more focused, leaner, and positioned to meet biopharmas emergent demand for enzymatic DNA with its LineaRx subsidiary.
• Dr. Hayward stated that the company's strategic priority is to elevate the execution of LineaRx and Applied DNA Clinical Labs to drive consistent and recurring revenues.
• Dr. Hayward believes industry tailwinds are accelerating.

Industry Context

The announcement highlights Applied DNA's focus on the growing market for enzymatic DNA production, particularly for biopharmaceutical applications. The company is positioning itself to capitalize on the increasing demand for DNA in genetic medicine and the limitations of traditional plasmid DNA manufacturing.

Comparison to Industry Standards

• The company's LineaRx segment competes with companies like Aldevron and GenScript in the synthetic DNA manufacturing market.
• The company believes its rapid DNA production and domestic sourcing capabilities are key differentiators.
• The company's Site 1 GMP facility, with an annual revenue capacity between $10 million and $30 million, is relatively small compared to larger CDMOs but is positioned to serve near-term manufacturing needs.
• The company's focus on PCR-based DNA production differentiates it from companies using other enzymatic DNA technologies.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth in the LineaRx segment and the expected decline in cash burn.
• Employees in the LineaRx segment may benefit from increased demand for their services.
• Customers may benefit from the company's new products and services, such as LineaPCR and LineaDNA IVT Evaluation Kits.

Next Steps

• Management will hold a conference call on June 3, 2025, to review the company's strategic priorities.
• The company expects to launch LineaPCR in Q425.
• The company expects large-scale manufacturing of the enzyme and buffer by a U.S.-based CDMO to begin in June 2025.

Key Dates

Keywords

LineaRx, LineaDNA, LineaIVT, Therapeutic DNA, PCR, mRNA, Diagnostics, Financial Results, Applied DNA Sciences, APDN